Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Vitespen Shows No Increased Survival in Postoperative Renal Cell Carcinoma Patients - (DGNews)
    European Commission Approves Methylnaltrexone Bromide for Opioid-Induced Constipation in Advanced Illness - (DGNews)
    HAART May Increase Asthma Risk in Children With HIV - (DGNews)
    Multitarget Immune Therapy Improves Outcomes of Severe Lupus Nephritis - (DGNews)
    Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty - (N Engl J Med)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Enhanced NSAID Delivery: Emerging Technologies
      The Use of Saline Nasal Irrigation in Common Upper Respiratory Conditions
      Balanced Opioid Prescribing
      Persistent, Not Permanent: Alleviating Symptoms in Chronic Knee Pain
      Update on the Management of Acute Decompensated Heart Failure: Incorporating Treatment Guidelines and Recent Clinical Research Findings into Practice

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Decrease in Tobacco Consumption After Treatment with Topiramate and Aripiprazole
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Successful Treatment of Kasabach-Merritt Syndrome with Vincristine and Surgery: A Case Report and Review of Literature
        Tender Nodules on the Palms and Soles After Chemotherapy
        Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        St John's Wort May Reduce Bioavailability of Conventional Medications

        British Medical Journal (BMJ)

        07/06/2004
        By Joene Hendry


        Conventional drugs may show reduced systemic bioavailability when taken concomitantly with Hypericum perforatum, the herbal supplement commonly known as St John's wort.

        Edward Mills, graduate fellow, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada, and colleagues systematically reviewed prospective clinical trials that assessed pharmacokinetic effect of St John's wort on the metabolism of a conventional drug.

        The conventional drugs in the 22 pharmacokinetic trials analysed included irinotecan, dextromethorphan and alprazolam, carbamazepine, digoxin, indinavir, tacrolimus and mycophenic acid or tacrolimus alone, cyclosporin A, oral contraceptives, midazolam, warfarin, amitriptyline, fexofenadine, simvastatin or pravastatin, omeprazole, and theophylline.

        "The methodological quality of the included studies was limited," the authors note.

        Overall, 18 of the studies did not have a control group. Of the 4 with control groups, 3 were randomised but did not describe the randomisation procedure, while 3 control groups received placebo but the placebo was not described. The studies were generally small with an average of 12 participants per study. Independent assays to determine the dosage of the St John's wort preparation occurred in 15 of the studies.

        The investigators assessed the magnitude of the interaction between St John's wort and the conventional drug by differences in the area under the curve (AUC) of the drug before and after challenge with St. John's wort. In the 19 trials with data on the systemic bioavailability of the conventional drugs in plasma, data from 15 reveals a decrease of greater than 20%.

        "Our review shows that St John's wort has the potential to reduce systemic bioavailability of many conventional drugs," the authors conclude, adding that clinicians and patients should be aware of this possibility. "Higher quality research is necessary to provide reliable information to guide clinical practice," they note.

        BMJ 2004;329:27-30, doi:10.1136/bmj.329.7456.27

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send